SIBN logo

SI-BONE, Inc. Stock Price

NasdaqGM:SIBN Community·US$848.4m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

SIBN Share Price Performance

US$18.93
3.39 (21.81%)
US$25.00
Fair Value
US$18.93
3.39 (21.81%)
24.3% undervalued intrinsic discount
US$25.00
Fair Value
Price US$18.93
AnalystConsensusTarget US$25.00
AnalystLowTarget US$20.00
AnalystHighTarget US$31.60

SIBN Community Narratives

·
Fair Value US$25 24.3% undervalued intrinsic discount

Expanding Minimally Invasive Procedures Will Open US And European Markets

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$20 5.4% undervalued intrinsic discount

Rising US Reimbursement Risk Will Curb Opportunities Yet Allow Recovery

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value US$31.6 40.1% undervalued intrinsic discount

Aging And Advancing Healthcare Will Expand Minimally Invasive Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$25
24.3% undervalued intrinsic discount
Profit Margin
12.49%
Future PE
40.89x
Price in 2028
US$30.49

Trending Discussion

No trending discussion available.

Updated Narratives

SIBN logo

SIBN: Refined 2026 Revenue Guidance And Assumptions May Support Measured Upside Potential

Fair Value: US$20 5.4% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
SIBN logo

Aging And Advancing Healthcare Will Expand Minimally Invasive Markets

Fair Value: US$31.6 40.1% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
SIBN logo

Expanding Minimally Invasive Procedures Will Open US And European Markets

Fair Value: US$25 24.3% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet.

2 Risks
4 Rewards

SI-BONE, Inc. Key Details

US$213.6m

Revenue

US$43.7m

Cost of Revenue

US$169.9m

Gross Profit

US$184.5m

Other Expenses

-US$14.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.33
79.53%
-6.85%
19.5%
View Full Analysis

About SIBN

Founded
2008
Employees
376
CEO
Laura Francis
WebsiteView website
si-bone.com

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Recent SIBN News & Updates

Analysis Article Aug 07

The SI-BONE, Inc. (NASDAQ:SIBN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

SI-BONE, Inc. ( NASDAQ:SIBN ) last week reported its latest second-quarter results, which makes it a good time for...
Narrative Update Aug 04

SIBN: Refined 2026 Revenue Guidance And Assumptions May Support Measured Upside Potential

Analysts have raised their price target on SI-BONE from $18.00 to $20.00, reflecting updated assumptions for fair value, discount rate, long term revenue growth, profit margins and future P/E multiples. What’s in the News for SI-BONE SI-BONE raised 2026 revenue guidance to a range of $231 million to $233 million, compared with the prior range of $230 million to $233 million.

Recent updates

No updates